• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 21, 2014

View Archived Issues

Regulatory front

Australia and New Zealand have called it quits on trying to form a joint regulatory agency to oversee drugs and medical devices. The decision followed a comprehensive review of the progress and an assessment of the costs and benefits to each country. Read More

In the clinic

Foundation Medicine Inc., of Cambridge, Mass., reported that interim findings from a phase II study of Boulder, Colo.-based Clovis Oncology Inc.'s rucaparib in patients with relapsed, platinum-sensitive ovarian cancer suggest that Foundation's companion diagnostic can identify both BRCA-mutant patients and non-BRCA-mutant patients who are more likely to benefit from rucaparib than patients who are biomarker negative. Read More

Other news to note

Alk-Abello A/S, of Horsholm, Denmark, said its registration application for the house dust mite sublingual allergy immunotherapy, or SLIT, tablet has been accepted for review by the European health authorities via the decentralized procedure with Germany as the reference member state. Read More

Stock movers

Read More

Financings

Northwest Biotherapeutics Inc., of Bethesda, Md., said it completed two financings totaling $35 million, which includes a $25 million equity investment by UK-based C.F. Woodford Equity Income Fund and a $10 million mortgage on the company's recently acquired UK facility. The mortgage has a two-year term and interest-only payments until maturity. Read More

FDA close to getting visa for inspectors in China

HONG KONG – The FDA has been planning for two years to expand its China office to meet significantly larger demands for inspections in the country. But for two years now, China has failed to approve visas for FDA staff, including inspectors brought in from the U.S. Read More

Post Viehbacher exit, Sanofi sets out its stall on late-stage pipeline

DUBLIN – A 2.5 percent share price drop – or a €2.5 billion (US$3 billion) loss of value – is not the best way to begin a pipeline update. But amid continued uncertainty about the leadership situation at Sanofi Group, that was the hand its chairman and interim CEO, Serge Weinberg, had to play as the company set out its stall Thursday on a late-stage pipeline that it contended will deliver cumulative revenues of €30 billion over the first five years of sales. Read More

Influenza drug targets become crystal clear

LONDON – The knowledge of the exact structure of the enzyme that the influenza virus uses to make new influenza viruses will give a huge boost to the search for drugs to treat that infection, scientists predict. Read More

ABPI: Changes needed to advance a stratified medicine approach

LONDON – The era of stratified medicines that are suitable for subgroups of patients only has arrived, but there are many shortcomings to address in terms of R&D, regulation, health technology assessment, access and reimbursement, to maintain momentum and ensure the benefits are delivered. Read More

Congress sweetening the pot for development of Ebola therapies

While most of the companies developing Ebola vaccines and therapies are getting considerable government support, several lawmakers are proposing another incentive – transferable priority review vouchers. Read More

Pharma: Other news to note

Purdue Pharma LP, of Stamford, Conn., said the FDA approved Hysingla ER (hydrocodone bitartrate), an extended-release opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe